Skip to main content
. 2025 May 30;12(3):367–381. doi: 10.1007/s40801-025-00492-z

Table 4.

Attitudes of HCPs towards ADR reporting

Statements Participant’s answer n (%)
Strongly disagree Disagree Agree Strongly agree
1. I know when a new medication is introduced, the majority of potential ADRs are already known. 451 (10.30) 1005 (23.0) 1870 (42.9) 1038 (23.80)
2. I know when reporting a suspected ADR contributes to patient safety. 17 (0.40) 102 (2.30) 737 (16.90) 3508 (80.40)
3. I do not know whose responsibility it is to report a suspected ADR. 1545 (35.40) 1287 (29.50) 1049 (24.00) 483 (11.10)
4. I would be more likely to report a suspected ADR if it was serious or if it was severe. 176 (4.00) 315 (7.20) 1036 (23.70) 2837 (65.0)
5. I would be MORE likely to report a suspected ADR if the adverse reaction occurred in an infant. 146 (3.30) 242 (5.50) 980 (22.50) 2996 (68.70)
6. I would be MORE likely to report a suspected ADR if the adverse event occurred in a pregnant woman than in a woman who was not pregnant. 388 (8.90) 484 (11.10) 1223 (28.00) 2269 (52.00)
7. I would be MORE likely to report a suspected ADR if the adverse event occurred in a person 65 years or older than in a patient less than 65 years of age. 377 (8.60) 551 (12.60) 1248 (28.60) 2188 (50.10)
8. I would be MORE likely to report a suspected ADR if it was a vaccine. 194 (4.40) 286 (6.60) 1136 (26.00) 2748 (63.00)
9. I would be MORE likely to report a suspected ADR if I was alerted to be looking for a specific adverse event 144 (3.30) 308 (7.10) 1383 (31.70) 2529 (58.00)
10. I would be MORE likely to report a suspected ADR if it was a newly approved medicine with new active pharmaceutical ingredient 96 (2.20) 179 (4.10) 1140 (26.10) 2949 (67.60)

N = 4364